Disease · MONDO_0005180

Parkinson disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Parkinson disease. Diseases, record MONDO_0005180. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005180

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Parkinson disease; Open Targets
Open Targets ID: MONDO_0005180; Open Targets
Other names: IDIOPATHIC PARKINSON DIS, IDIOPATHIC PARKINSONS DIS, Idiopathic PD, Idiopathic Parkinson Disease, Idiopathic Parkinson's Disease, LEWY BODY PARKINSON DIS, Lewy Body Parkinson Disease, Lewy Body Parkinson's Disease, PARKINSON DIS, PARKINSON DIS IDIOPATHIC, PARKINSONS DIS, PARKINSONS DIS IDIOPATHIC, PARKINSONS DIS LEWY BODY, PD, Parkinson Disease, Idiopathic, Parkinson syndrome, Parkinson's, Parkinson's Disease, Idiopathic, Parkinson's Disease, Lewy Body, Parkinson's disease, Parkinson's disease (disorder), Parkinson's disease NOS, Parkinson's disease NOS (disorder), Parkinson's syndrome, Parkinsonian disorder, Parkinsonism, Primary, Parkinsons, Parkinsons disease, Primary Parkinsonism, paralysis agitans; Open Targets
Disease Ontology: DOID:14330; Disease Ontology
MeSH: D010300; MeSH
NCI Thesaurus: C26845; NCI Thesaurus
Orphanet: ORPHA:319705; Orphanet
Highest stage of its drugs: Approval, for 57 of its 333 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs333

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVODOPA	CHEMBL1009	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs, PMDA and TTD	196	134	125	Drugs and targets
CARBIDOPA	CHEMBL1200748	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	138	76	73	Drugs and targets
ROTIGOTINE	CHEMBL1303	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs and PMDA	58	50	46	Drugs and targets
PRAMIPEXOLE	CHEMBL301265	Small molecule	Approval	ATC, EMA Human Drugs and TTD	46	38	38	Drugs and targets
ENTACAPONE	CHEMBL953	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs, PMDA and TTD	48	30	24	Drugs and targets
RASAGILINE	CHEMBL887	Small molecule	Approval	ATC, EMA Human Drugs and TTD	34	29	29	Drugs and targets
APOMORPHINE	CHEMBL53	Small molecule	Approval	ATC and TTD	31	28	27	Drugs and targets
ROPINIROLE	CHEMBL589	Small molecule	Approval	ATC and TTD	23	21	21	Drugs and targets
ISTRADEFYLLINE	CHEMBL431770	Small molecule	Approval	ATC, DailyMed, FDA, PMDA and TTD	25	19	19	Drugs and targets
AMANTADINE	CHEMBL660	Small molecule	Approval	ATC	19	18	18	Drugs and targets

1 to 10 of 333

See all 333 drugs

Targets284

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	19	D2-like dopamine receptor agonist; Dopamine D2 receptor agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist; Dopamine receptor agonist; Dopamine receptors; D2 & D3 partial agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D(3) dopamine receptor	16	D2-like dopamine receptor agonist; Dopamine D3 receptor agonist; Dopamine D3 receptor antagonist; Dopamine receptor agonist; Dopamine receptors; D2 & D3 partial agonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D(4) dopamine receptor	12	D2-like dopamine receptor agonist; Dopamine D4 receptor agonist; Dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	11	Muscarinic acetylcholine receptor M1 agonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 positive allosteric modulator	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
GRIN1	Glutamate NMDA receptor; GRIN1/GRIN2B	10	Glutamate NMDA receptor; GRIN1/GRIN2B antagonist; Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Approval	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	10	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist	Approval	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate NMDA receptor; GRIN1/GRIN2B	10	Glutamate NMDA receptor; GRIN1/GRIN2B antagonist; Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Approval	https://conductscience.org/library/genes/2904	Drugs and targets
SCN5A	Sodium channel alpha subunit	9	Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker	Approval	https://conductscience.org/library/genes/6331	Drugs and targets
ADORA2A	Adenosine A2 receptor	8	Adenosine A2 receptor antagonist; Adenosine A2a receptor antagonist; Adenosine A2a receptor inverse agonist; Adenosine receptor antagonist	Approval	https://conductscience.org/library/genes/135	Drugs and targets
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	8	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets

1 to 10 of 284

See all 284 targets

Trials712

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 36 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01270711	Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)		22,014	2014-03-24	Parkinson's Disease, Hyperprolactinemia	CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT01361009	a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients		2,017	2013-08-30	Parkinson Disease	PRAMIPEXOLE	Its record names the disease	ClinicalTrials.gov
NCT00449865	NET-PD LS-1 Creatine in Parkinson's Disease	Phase 3	1,741	2015-04-02	Parkinson's Disease	CREATINE	Its record names the disease	ClinicalTrials.gov
NCT00256204	A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease	Phase 3	1,174	2011-06-21	Parkinson's Disease	RASAGILINE	Its record names the disease	ClinicalTrials.gov
NCT01155479	A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)	Phase 3	1,022	2016-07-28	Parkinson Disease	PRELADENANT, RASAGILINE	Its record names the disease	ClinicalTrials.gov
NCT03727139	Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"		1,021	2024-03-08	Parkinson's Disease	RASAGILINE	Its record names the disease	ClinicalTrials.gov
NCT00360412	A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Phase 3	997	2013-02-05	Parkinson's Disease	PERAMPANEL	Its record names the disease	ClinicalTrials.gov
NCT01215227	An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)	Phase 3	839	2016-12-12	Parkinson Disease, Idiopathic Parkinson Disease	PRELADENANT	Its record names the disease	ClinicalTrials.gov
NCT01155466	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)	Phase 3	778	2016-02-11	Parkinson Disease	PRELADENANT	Its record names the disease	ClinicalTrials.gov
NCT00368108	Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Phase 3	752	2013-02-05	Parkinson's Disease	PERAMPANEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 712

See all 712 trials

Comparisons in its trials204

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Creatine vs Placebo: serious adverse events	315 of 874	347 of 867	1,741	NCT00449865	Trial comparisons
Perampanel (Perampanel 2 mg or 4 mg During Core Study) vs Perampanel (Placebo During Core Study): serious adverse events	57 of 664	33 of 333	997	NCT00360412	Trial comparisons
Carbidopa/Levodopa/Entacapone vs Carbidopa/Levodopa: serious adverse events	91 of 373	84 of 371	744	NCT00099268	Trial comparisons
Carbidopa/Levodopa/Entacapone vs Carbidopa/Levodopa: Occurrence of Wearing-off	139 of 305	161 of 333	638	NCT00099268	Trial comparisons
Carbidopa/Levodopa/Entacapone vs Carbidopa/Levodopa: Occurrence of Dyskinesia	128 of 307	103 of 318	625	NCT00099268	Trial comparisons
Exelon Capsule vs Exelon Patch: serious adverse events	87 of 294	83 of 288	582	NCT00623103	Trial comparisons
DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Infusion Related Reactions (IRRs)	32 of 292	37 of 290	582	NCT04777331	Trial comparisons
DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Treatment Discontinuation Due to AEs	2 of 292	3 of 290	582	NCT04777331	Trial comparisons
DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Adverse Events of Special Interest (AESI)	0 of 292	0 of 290	582	NCT04777331	Trial comparisons
DBT Period: Prasinezumab vs DBT Period: Placebo: deaths from any cause	1 of 292	2 of 290	582	NCT04777331	Trial comparisons

1 to 10 of 204

See all 204 comparisons in its trials

Papers from its trials365

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41316871	RESULT	1	PubMed
39775041	RESULT	1	PubMed
39251680	RESULT	1	PubMed
38598572	RESULT	1	PubMed
36449420	RESULT	1	PubMed
35274200	RESULT	1	PubMed
34496081	RESULT	1	PubMed
34224829	RESULT	1	PubMed
33164945	RESULT	1	PubMed
32871874	RESULT	1	PubMed

1 to 10 of 365

See all 365 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005180

GET https://conductscience.org/api/diseases/v1/MONDO_0005180/drugs?page=2

API reference For AI assistants